Corona Crisis from 2020

Will we survive death?

by

Death, the killer virus SARS-CoV2 and our collective fear

Recently, US philanthropist Robert T. Bigelow, who runs his own institute, offered what is believed to be the highest amount of money awarded for frontier research, if not in the scientific enterprise at all; only the Nobel Prizes are higher, as far as I know. A total of 1.8 million dollars is to be awarded for a text that irrevocably proves that death does not mean the absolute end of consciousness. The award ceremony is taking place in Las Vegas, Nevada, these days.

Bigelow is an aerospace entrepreneur who used to work on remote Earth habitats for NASA and still has many contracts with all sorts of aerospace companies and makes his money from them. He probably experienced a conversion experience of his own, much like astronaut Edgar Mitchell, who, while flying back to Earth from the Moon, famously described the beauty of the Earth and its embeddedness in a cosmic whole as a spiritual experience that changed him. Mitchell went on to found the “Institute of Noetic Sciences” in Petaluma, California. Much like Bigelow: He founded his own institute and has used his money over the years to fund academics who tread unusual paths, such as Charlie Tart, who studies extraordinary states of consciousness.

Read more

New Data And Analyses on The Corona Situation

by

The Pfizer pivotal study is compromised and unreliable

A new paper in the British Medical Journal reveals that and how the Pfizer trial that led to the approval of the BioNTech vaccine was compromised [1]. Paul Thacker, an investigative journalist, reports on a whistleblower, Brook Jackson, who worked at one of the clinical centres, Ventavia in Texas. Ventavia is one of the largest clinical research service providers in Texas and was one of the companies that organized patients for the clinical trial and managed their data. These were “only” 1,000 of the approximately 53,000 patients, but the reported conditions speak volumes. For Jackson had repeatedly pointed out to the company management errors in implementation, poor data quality, patients whose complaints were not followed up, side effects that were not neatly registered, unblinding and any number of other problems.

It’s worth reading in the original. The bad thing is: Jackson had brought this to the attention of the US regulatory authority, the FDA. The FDA had neither replied nor pointed out the problems in its approval report. Instead, the whistleblower was dismissed without notice on the very day she reported the matter to the FDA. Research by the journalist shows that other employees who wished to remain anonymous confirmed the statements.

Read more